--Novartis AG is considering selling assets including its respiratory and ophthalmology businesses as it seeks to invest in innovative medicines, Bloomberg reports, citing unnamed sources.

--The Swiss pharma major's ophthalmology business alone could be worth about $5 billion, according to Bloomberg.

--Any sales of the businesses are likely to start in 2023 but there is no certainty that the deliberations will result in disposals, Bloomberg reports.


Full story: https://bloom.bg/3txZE7V


Write to Cecilia Butini at cecilia.butini@wsj.com


(END) Dow Jones Newswires

11-16-22 1002ET